Novo Nordisk A/S (NYSE:NVO) Holdings Decreased by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 0.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 73,719 shares of the company’s stock after selling 145 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in Novo Nordisk A/S were worth $6,341,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Marco Investment Management LLC raised its position in Novo Nordisk A/S by 1.5% in the third quarter. Marco Investment Management LLC now owns 6,702 shares of the company’s stock worth $798,000 after acquiring an additional 100 shares in the last quarter. Menard Financial Group LLC grew its stake in shares of Novo Nordisk A/S by 0.8% in the 3rd quarter. Menard Financial Group LLC now owns 12,283 shares of the company’s stock worth $1,463,000 after purchasing an additional 102 shares during the last quarter. Optimist Retirement Group LLC raised its holdings in shares of Novo Nordisk A/S by 4.3% in the 3rd quarter. Optimist Retirement Group LLC now owns 2,747 shares of the company’s stock worth $327,000 after purchasing an additional 112 shares in the last quarter. Financial Counselors Inc. boosted its holdings in Novo Nordisk A/S by 1.1% during the third quarter. Financial Counselors Inc. now owns 11,009 shares of the company’s stock worth $1,311,000 after buying an additional 115 shares in the last quarter. Finally, M. Kulyk & Associates LLC grew its position in Novo Nordisk A/S by 3.9% in the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock worth $274,000 after buying an additional 119 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.4 %

NYSE:NVO opened at $76.88 on Friday. The stock has a market cap of $344.98 billion, a PE ratio of 23.37, a price-to-earnings-growth ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $73.80 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock’s 50-day moving average is $83.34 and its two-hundred day moving average is $101.22.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This represents a yield of 1.2%. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is 47.72%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on NVO shares. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Friday. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.